Please assess the completion status of the following clinical trial:

Trial Title: Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women aged 18-65 years;~2. Integrase inhibitor-naive subjects with clinical indication to initiate RAL under the supervision of their HIV care provider;~3. Baseline detectable HIV-1 RNA levels ≥ 5000 copies/mL in plasma and ≥ 500 copies/mL in CSF;~4. Absolute T-cell CD4+ subset between 200-500/mm3~5. Individual willing to undergo serial lumbar punctures as outlined in study evaluations;~6. Subject able to give informed consent to all study procedures (if cognitively impaired, the individual must pass an evaluation to ensure adequate comprehension of the consent document and procedures);~7. Susceptibility to all study drugs on Monogram Biosciences PhenoSense GT assay.~Exclusion Criteria:~1. Contraindication to lumbar puncture, such as current coagulopathy, thrombocytopenia (platelets below 50,000/µL), or use of anticoagulants;~2. Cognitive, psychiatric, or substance use disorders or any other medical conditions that would interfere with study participation, in the opinion of the investigator;~3. Major opportunistic infections (e.g., pneumonia, tuberculosis) within 30 days;~4. Use of prescribed drugs with known substantial interactions with the study drugs;~5. Positive HCV serology;~6. HIV-associated dementia/Global Deterioration Scale ≥4;~7. Pregnancy;~8. Serum creatinine higher than 2.0 mg/dL;~9. Total bilirubin or alanine or aspartate transaminases more than 3 times the upper limit of normal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Raltegravir (Type: EXPERIMENTAL): None
- Efavirenz (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).